<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="776">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151055</url>
  </required_header>
  <id_info>
    <org_study_id>RD2019-01</org_study_id>
    <nct_id>NCT05151055</nct_id>
  </id_info>
  <brief_title>Lactoferrin + Vitamin E + Zinc for Hormonal Acne</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial To Determine The Safety and Efficacy of Lactoferrin With Vitamin E and Zinc as an Oral Therapy for Mild to Moderate Hormonal Acne in Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Laboratories</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We previously showed that twice daily intake of a combination of 100 mg lactoferrin, 11 IU&#xD;
      vitamin E, and 5 mg zinc significantly reduced both inflammatory and non-inflammatory acne&#xD;
      lesions compared to placebo control. In that study, females showed an overall better response&#xD;
      compared to males in terms of total lesions. We speculated that the gender effect may be due&#xD;
      to mitigation of the pre- menstrual flare-ups women have that lead to recurring acne, making&#xD;
      them have a better response. The objectives of this study are: 1.) to characterize the&#xD;
      efficacy and safety of 100 mg lactoferrin + 11 IU vitamin E + 5 mg zinc in the adult female&#xD;
      population who suffer from hormonal acne, 2.) to determine whether the anti-acne effect is&#xD;
      maintained after treatment stops.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change in inflammatory acne lesions at 2, 4, 6, 8, 10, and 12 weeks compared to baseline, in the treatment versus placebo groups</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in inflammatory acne lesion counts at 14, 16, 18, 20, 22, and 24 weeks compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change in the AFAST scores at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 weeks compared to baseline, in the treatment versus placebo groups</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Hormonal Acne</condition>
  <arm_group>
    <arm_group_label>Lactezin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactezin</intervention_name>
    <description>100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)</description>
    <arm_group_label>Lactezin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>starch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged 22-50.&#xD;
&#xD;
          2. At least 3 inflammatory acne lesions, mostly found on (but not limited to) the lower&#xD;
             face&#xD;
&#xD;
          3. Not responsive to conventional treatment&#xD;
&#xD;
          4. Clinical diagnosis of mild to moderate acne according to Lehmann et. al.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant (confirmed by a pregnancy test), breast- feeding, or planning&#xD;
             a pregnancy.&#xD;
&#xD;
          2. Post-menopausal women&#xD;
&#xD;
          3. Current or recent (within 3 months) use of any topical or oral anti- acne products,&#xD;
&#xD;
          4. Hormonal contraceptive intake in the preceding six months&#xD;
&#xD;
          5. A cancer diagnosis within the past 5 years&#xD;
&#xD;
          6. History of hypersensitivity to any component of the test product.&#xD;
&#xD;
          7. Current imuunosuppression. Specifically, these include patients with co-morbidities&#xD;
             such as diabetes, HIV, chronic diseases patients requiring maintenance medications,&#xD;
             such as vascular disease,&#xD;
&#xD;
               -  hepatitis, eczema, psoriasis, or acute febrile/infectious illnesses&#xD;
&#xD;
               -  (i.e. Dengue, pneumonia, etc)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliene Lim, Ph.D.</last_name>
    <phone>63288581000</phone>
    <email>jgco@unilab.com.ph</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Management and Testing Associates, Inc.</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gertrude Chan, M.D.</last_name>
      <phone>(632) 659-3238</phone>
      <email>clintrialtest@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 28, 2021</last_update_submitted>
  <last_update_submitted_qc>November 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

